Reports

Drug name	NICE TAs	Comments
Sucroferric oxyhydride		Under review.
Sucroferric oxyhydroxide (Velphoro)		2nd or 3rd line agent. Specialist use.
Sugammadex		Restricted use as per protocol
Sulfasalazine#10.1		ESCA
Sulindac tablets		Polyhydramnios (women only)
Sulpiride tablets		ESCA
Sunitinib capsules	TA178 - Bevacizumab (first-line), sorafenib (first- and second-line), sunitinib (second-line) and temsirolimus (first-line) for the treatment of advanced and/or metastatic renal cell carcinoma (Negative TA) TA169 - Sunitinib for the first-line treatment of advanced and/or metastatic renal cell carcinoma TA179 - Sunitinib for the treatment of gastrointestinal stromal tumours TA449 - Everolimus and sunitinib for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease	Hospital use only
Tacrolimus 0.1% w/w in OrabaseTM		Unlicensed special
Tacrolimus 0.3% w/w in OrabaseTM		Unlicensed special
Tacrolimus capsules (Prograf)	TA85 - Immunosuppressive therapy for renal transplantation in adults	New post-transplant

University Hospitals Birmingham NHS Foundation Trust